Gefitinib versus placebo in completely resected non–small-cell lung cancer: results of the NCIC CTG BR19 study
Purpose Survival of patients with completely resected non–small-cell lung cancer (NSCLC)
is unsatisfactory, and in 2002, the benefit of adjuvant chemotherapy was not established …
is unsatisfactory, and in 2002, the benefit of adjuvant chemotherapy was not established …
Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study
GD Goss, C O'Callaghan, I Lorimer… - Journal of clinical …, 2013 - pubmed.ncbi.nlm.nih.gov
Purpose Survival of patients with completely resected non-small-cell lung cancer (NSCLC)
is unsatisfactory, and in 2002, the benefit of adjuvant chemotherapy was not established …
is unsatisfactory, and in 2002, the benefit of adjuvant chemotherapy was not established …
Gefitinib versus placebo in completely resected non-small-cell lung cancer: Results of the NCIC CTG BR19 study
GD Goss, C O'Callaghan… - Journal of …, 2013 - utsouthwestern.elsevierpure.com
Purpose Survival of patients with completely resected non-small-cell lung cancer (NSCLC)
is unsatisfactory, and in 2002, the benefit of adjuvant chemotherapy was not established …
is unsatisfactory, and in 2002, the benefit of adjuvant chemotherapy was not established …
[HTML][HTML] Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study
GD Goss, C O'Callaghan, I Lorimer… - Journal of Clinical …, 2013 - ncbi.nlm.nih.gov
Purpose Survival of patients with completely resected non–small-cell lung cancer (NSCLC)
is unsatisfactory, and in 2002, the benefit of adjuvant chemotherapy was not established …
is unsatisfactory, and in 2002, the benefit of adjuvant chemotherapy was not established …
Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.
GD Goss, C O'Callaghan, I Lorimer… - Journal of Clinical …, 2013 - europepmc.org
Purpose Survival of patients with completely resected non-small-cell lung cancer (NSCLC)
is unsatisfactory, and in 2002, the benefit of adjuvant chemotherapy was not established …
is unsatisfactory, and in 2002, the benefit of adjuvant chemotherapy was not established …
[引用][C] Gefitinib Versus Placebo in Completely Resected Non―Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study
GD GOSS, C O'CALLAGHAN… - Journal of clinical …, 2013 - pascal-francis.inist.fr
Gefitinib Versus Placebo in Completely Resected Non―Small-Cell Lung Cancer: Results of
the NCIC CTG BR19 Study CNRS Inist Pascal-Francis CNRS Pascal and Francis …
the NCIC CTG BR19 Study CNRS Inist Pascal-Francis CNRS Pascal and Francis …
Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study
GD Goss, C O'Callaghan, I Lorimer, MS Tsao… - Journal of Clinical …, 2013 - cir.nii.ac.jp
< jats: sec>< jats: title> Purpose</jats: title>< jats: p> Survival of patients with completely
resected non–small-cell lung cancer (NSCLC) is unsatisfactory, and in 2002, the benefit of …
resected non–small-cell lung cancer (NSCLC) is unsatisfactory, and in 2002, the benefit of …
[PDF][PDF] Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study
GD Goss, C O'Callaghan, I Lorimer, MS Tsao… - Clinical …, 2011 - academia.edu
Purpose Survival of patients with completely resected non–small-cell lung cancer (NSCLC)
is unsatisfactory, and in 2002, the benefit of adjuvant chemotherapy was not established …
is unsatisfactory, and in 2002, the benefit of adjuvant chemotherapy was not established …
[PDF][PDF] Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study
GD Goss, C O'Callaghan, I Lorimer, MS Tsao… - Clinical …, 2011 - researchgate.net
Purpose Survival of patients with completely resected non–small-cell lung cancer (NSCLC)
is unsatisfactory, and in 2002, the benefit of adjuvant chemotherapy was not established …
is unsatisfactory, and in 2002, the benefit of adjuvant chemotherapy was not established …
Gefitinib versus placebo in completely resected non-small-cell lung cancer: Results of the NCIC CTG BR19 study
GD Goss, C O'Callaghan, I Lorimer… - Journal of Clinical …, 2013 - experts.illinois.edu
Purpose Survival of patients with completely resected non-small-cell lung cancer (NSCLC)
is unsatisfactory, and in 2002, the benefit of adjuvant chemotherapy was not established …
is unsatisfactory, and in 2002, the benefit of adjuvant chemotherapy was not established …